Key result
Recent advances in pharmacological and nonpharmacological treatments have improved chronic heart failure prognosis, though challenges such as HFpEF management and recurrent hospitalizations remain.
有する患者を既往も含め「ステージC 心不全 ステージ」 ，おおむね年間2回以上の心不全入院 を繰り返し，有効性が確立しているすべての薬 物治療・非薬物治療について治療ないしは治療 が考慮されたにもかかわらずニューヨーク心臓 協会(New York Heart Association：NYHA)心機 九州大学大学院医学研究院循環器内科学 115 th Scientific Meeting of the Japanese Society of Internal Medicine：Panel Discussion：Management and pitfalls in daily practice for intractable diseases；2.Advances and limitations of pharmacological and nonpharmacological treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Hiroyuki Tsutsui (2018) conducted a review in Chronic heart failure. Pharmacological and nonpharmacological treatments (ARNI, ivabradine, SGLT2 inhibitors) was evaluated. Recent advances in pharmacological and nonpharmacological treatments have improved chronic heart failure prognosis, though challenges such as HFpEF management and recurrent hospitalizations remain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: